Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

1606 Corp starts campaign to bring ChatCBDW to over 3,000 CBD merchants throughout the US

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news the company has announced a significant strategic move to launch a dedicated sales team for their product, ChatCBDW, an AI-powered merchandising Chatbot designed for the CBD industry. This initiative is set to begin with a targeted email-based marketing campaign in December, with a focus on reaching over 3,000 CBD merchants across the United States. Lambrecht shared that the company has enlisted the expertise of marketing professional Derek McCarthy to lead this ambitious outreach program. The primary objective is to personally engage with every CBD company in the US and introduce them to the capabilities of ChatCBDW. The goal is to showcase how this AI-powered tool can significantly boost sales conversions and enhance customer education efforts for CBD merchants. McCarthy, who brings with him 17 years of experience in sales and marketing, as well as a deep understanding of AI technologies for communication, emphasized the team's mission to tap into the transformative potential of ChatCBDW. The sales and marketing efforts will kick off in early December through a comprehensive email marketing campaign, complemented by a national call strategy. This strategic move by 1606 Corp represents a significant step in expanding their presence and influence within the CBD industry, positioning ChatCBDW as a valuable asset for CBD merchants seeking to enhance their customer engagement and sales processes. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

December 06, 2023 01:24 PM Eastern Standard Time

Video

HKBU-led research develops novel drug delivery system for Gouteng compound for Alzheimer’s disease treatment

Hong Kong Baptist University

HONG KONG SAR - Media OutReach Newswire - 6 December 2023 - A research team led by Hong Kong Baptist University (HKBU) has developed a novel drug delivery system for Alzheimer's disease (AD). The researchers have engineered exosomes, extracellular vesicles released by cells, to effectively carry the bioactive compound Corynoxine-B extracted from the Chinese herbal medicine Gouteng to the brain of mice with AD. As Corynoxine-B can induce autophagy, a process that maintains the health of cells, this new drug delivery system using exosomes can improve cognitive function and movement while reducing the symptoms of AD. The research findings have been published in the international academic journal Nature-Signal Transduction and Targeted Therapy. Bioactive compound of Gouteng can treat AD AD is the most common type of dementia in which the brain cells degenerate and die, characterised by a build-up of amyloid-beta and phospho-tau protein in the brain, resulting in the decline of the brain's cognitive functions. Currently more than 55 million people worldwide are dementia patients. In Hong Kong more than 100,000 elderly suffer from dementia and the number is anticipated to soar to more than 330,000 by 2039. At present there is no curative treatment for AD. Available treatments can only delay the disease's progression and improve symptoms. HKBU's previous research projects found that Corynoxine-B, a bioactive compound of Gouteng, is effective in treating AD. However, the blood-brain barrier which protects the brain from potentially harmful substances in the bloodstream affects its uptake in brain. Exosomes serve as drug carriers To tackle this problem, a research team comprising Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine, and Dr Ashok Iyaswamy, Research Assistant Professor of the Teaching and Research Division at the School of Chinese Medicine at HKBU, along with other local, mainland and overseas scientists, have developed a novel approach to deliver Corynoxine-B to the brain using exosomes. Exosomes are extracellular vesicles released by cells which can transport molecules between cells like nanocarriers. Recent studies have shown that they could be utilised as vehicles for drug delivery. To examine whether exosomes are effective drug carriers for AD, the researchers manipulated the neuronal cells in mice to overexpress an adaptor protein Fe65 on the surface of exosomes released by these cells. Fe65 is involved in the processing of amyloid-beta precursor protein (APP), which plays a crucial role in the development of AD. By doing so, they observed more exosomes containing Fe65 were released by the neuronal cells. These engineered exosomes showed a good ability to migrate towards the neuronal cells with APP overexpressed in AD models. These findings suggest that the presence of Fe65 on the surface of exosomes enhanced their ability to specifically target and interact with the neuronal cells with elevated levels of APP, which is a characteristic feature of AD. Reduction of accumulated amyloid-beta protein Corynoxine-B is a natural inducer of autophagy which plays a crucial role in maintaining neuronal health. The research team loaded it into the engineered exosomes and injected it to the mice with AD to evaluate its potential as a therapeutic agent for the disease. Results show that engineered exosomes loaded with Corynoxine-B could enhance autophagy in mice, and were able to cross the blood-brain barrier to deliver Corynoxine-B to the brain, resulting in a 30% reduction of accumulated amyloid-beta protein. In addition, various behavioural tests including the rotarod test, open field test, contextual fear conditioning test, and Morris's water maze test conducted on mice with AD showed that the application of engineered exosomes loaded with Corynoxine-B resulted in 25% recovery of the cognitive and locomotor behaviour. Professor Li Min said: "Our study suggests that exosomes could be a promising new way to deliver drugs to the brain and treat AD. More research is needed, but this study provides hope that a cure for AD may be possible in the future. We hope that this research project will ultimately be beneficial to the elderly, individuals at high risk of neurodegeneration and neurodegenerative disease patients." Contact Details Hong Kong Baptist University (HKBU) Christina Wu christinawu@hkbu.edu.hk

December 06, 2023 09:00 AM Eastern Standard Time

Microsoft Shareholder Seeks Accountability for Transgender Policies; Opposes Reid Hoffman for Board

NLPC

At the annual meeting for Microsoft Corporation on Thursday, National Legal and Policy Center will present a shareholder proposal that demands the company deliver an analysis of potential discrimination in the insurance coverage it offers employees, as it pertains to gender. Specifically, NLPC has identified coverage for so-called “transgender” staffers who desire to switch from their birth sex. Meanwhile the tech giant – otherwise generous in its benefits coverage, which includes paying for women to travel out of their home states to get abortions, if it’s unlawful where they live – has no provisions in its health plans for those who rue their life-altering “transition” decisions. In support of the proposal, NLPC also filed a proxy memo with the Securities and Exchange Commission, which explains in greater detail the reasons why shareholders should support its resolution for the Microsoft meeting, which is Proposal 5 on the company’s proxy statement. As the nonprofit shareholder reports, the Equal Employment Opportunity Commission prohibits discrimination “in the payment of wages or employee benefits” based on gender, and thus Microsoft’s failure to accommodate de-transitioning workers is clearly biased and inequitable treatment. “A ‘de-transitioner’ fits into Dept. of Labor- and EEOC-protected categories of prohibited discrimination, which include ‘sex’ – expressly incorporating ‘gender identity’ and ‘sexual orientation,’” NLPC reported. “Arguably, for a ‘de-transitioner,’ the protected categories of ‘disability’ and/or ‘genetic information’ could also be cited as possible bases for discrimination.” “While Microsoft boasts about its perfect score from the Human Rights Campaign for capitulating to their radical LGBT agenda, those who are permanently scarred as a consequence of their policies have nowhere to turn for help,” said Paul Chesser, director of NLPC’s Corporate Integrity Project. As NLPC’s proposal states, many regretful transitioners are harmed with “various long-lasting side effects like chronic pain, sexual dysfunction, unwanted hair loss and hair gain, menstrual irregularities, urinary problems, and other complications. Rather than resolve mental health problems, such ‘gender affirming’ care instead often exacerbates them.” NLPC also notes how sufferers are becoming increasingly litigious, which could present material risk to Microsoft shareholders, as noted in the proxy memo to the SEC: Michelle Zacchigna had her uterus and breasts removed, and is suing the eight providers who treated her over their “recklessness.” “Distress related to my gender was treated to the exclusion of other serious mental health issues which went undiagnosed for years. Blind affirmation of my stated identity closed the door to alternative treatment options. What happened to me should never happen again.” Those who desire to “de-transition” cannot find needed treatment, whether from providers or insurance companies… Prisha Mosley said every primary care physician, endocrinologist, obstetrician, and gynecologist she’s approached on her insurance list has turned her away or said they can’t help. “I could call and be rejected every single day.” Chloe Cole said, “I reached out to every physician, every therapist who is involved with this, and I haven’t really gotten any help at all.” Cat Cattinson said, “Because of the experimental nature of gender medicine, doctors know very little about the long-term effects of medical transition and even less about the health-care needs of those who de-transition.” “Microsoft is not only vulnerable legally and financially because it fails to cover care for de-transitioners,” Chesser said, “but also because the company’s stated policies affirm it is possible to change one’s gender. If a judge and jury were to decide the company lied and convinced an employee into undergoing chemical or surgical castration, that is a material risk that Microsoft must disclose in its 10-K annual report to shareholders.” In addition to its shareholder proposal, NLPC also filed another proxy memo with the SEC to oppose the re-election of LinkedIn co-founder Reid Hoffman for Microsoft’s board of directors. The move follows a letter that Chesser sent to Microsoft’s board in October, which asked for the removal of the tech billionaire from the board, due to his hyper-partisan political activities and his connections to the late convicted pedophile Jeffrey Epstein. Founded in 1991, NLPC promotes ethics in public life and government accountability through research, investigation, education, and legal action. ### For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

December 05, 2023 01:35 PM Eastern Standard Time

News Release

BioHarvest Sciences reports 113% year over year increase in revenue on strong sales of VINIA

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to reveal the company's 3Q 2023 results, which demonstrate remarkable growth for its flagship product, VINIA. The company achieved its projected $3.24 million in revenue for the quarter, representing a 113% increase compared to the same quarter last year and an 18% increase compared to Q2 2023. Sobel also highlighted the significant improvement in the company's gross profit margin, which reached 45% in Q3 2023 compared to 18% in Q3 2022 and 40% in Q2 2023. This margin is expected to continue to rise as production scales up. In addition, BioHarvest Sciences has seen substantial growth in its total active network of subscribers, which has increased by 213% compared to Q3 2022. The company generates 90% of its revenue from subscriptions, with 95% of subscribers on plans of 3 months or more, and 23% on plans of 6 months or more. Furthermore, VINIA continues to expand its product sales on Amazon.com, with Q3 Amazon revenue increasing by 84% over Q2 2023. These positive results demonstrate the strong demand for BioHarvest Sciences' innovative products and its successful growth strategies. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

December 05, 2023 01:28 PM Eastern Standard Time

Video

Arecor Therapeutics reveals deal with "global medical products company"

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC) Chief Business Officer Manjit Rahelu speaks to Thomas Warner from Proactive after the biopharmaceutical group announced a significant development from its Specialty Hospital division. A new collaboration with an unspecified "global medical products company" will focus on reformulating a blockbuster oncology drug into a ready-to-use liquid form, enhancing its efficiency and ease of use for patients. This marks a significant shift from its powdered form, which was complex and time-consuming to prepare. The reconstituted drug is not only more convenient but also aims to reduce waiting times for patients, thereby improving overall healthcare delivery. Dr. Rahelu highlighted the collaborative effort involving a global partner with expertise in R&D, manufacturing, commercialisation, and regulatory affairs. This partnership aims to leverage both entities' strengths, combining Arecor's innovative in-house development with the partner's global capabilities. Arecor's technology has been instrumental in this advancement, underscoring their capability to apply their technology across various therapeutic areas beyond diabetes. This development is the second major outcome from Arecor's in-house pipeline and Rahelu says it demonstrates Arecor's ability to independently identify and develop promising candidates, translating R&D efforts into value-driving collaborations. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 05, 2023 12:09 PM Eastern Standard Time

Video

Oncimmune "relaunch" already delivering results

Oncimmune Holdings PLC

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone speaks to Thomas Warner from Proactive London about what he describes as the relaunch of the business. Gouldstone discusses the significant changes made to the company's strategy following his appointment in August, saying that his primary focus has been on maximising the commercial and scientific value of the company's Immune Insights platform, centred in their Dortmund labs. The new strategy, announced on October 12th, aims to expand the platform's capabilities in drug discovery and development and reach different customer verticals, extending from big pharma to smaller biopharma and CRO partnerships. With extensive industry experience dating back to 1990, including roles in major CROs and corporate finance, Gouldstone brings a wealth of expertise to Oncimmune. Since taking the helm, he has conducted a comprehensive review of the business, covering everything from finances to operations. The outcome has been positive, with a productive team in Germany, established relationships with large pharma, and a growing commercial team. Gouldstone's short tenure has already seen tangible successes, including the signing of four deals aligned with the new strategy, indicating early commercial traction. He anticipates continued growth and success in line with the company's evolving strategy and robust pipeline. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 05, 2023 12:00 PM Eastern Standard Time

Video

PathAI Announces Research Presentations at the San Antonio Breast Cancer Symposium

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced it will present four research presentations underscoring the value and potential of PathExplore’s* human interpretable features (HIFs), and one research presentation demonstrating the ability of the AIM-HER2* product to accurately predict HER2 scores, including in HER2-low cases, at the San Antonio Breast Cancer Symposium on December 5-9, 2023, in San Antonio, TX. “This research builds on our past successes and proceeds to show that PathAI’s algorithms continue to further our understanding of cancer biology and disease mechanisms,” said Andy Beck, M.D., Ph.D., co-founder and chief executive officer of PathAI. “At PathAI, we continue to demonstrate the clinical potential for these AI pathology tools, and we’re confident that it will ultimately translate to advancements in precision medicine and patient outcomes.” Poster #PO1-07-01: Artificial Intelligence-based prediction of Oncotype DX score from whole slide images using human-interpretable features and breast biomarkers The Oncotype DX Breast Recurrence Score assay (ODX) is a commonly used genomic test for patients with estrogen receptor (ER)-positive, HER2-negative, early-stage invasive breast cancer. While ODX predicts patients’ recurrence risk and benefit from chemotherapy, it is time-consuming and expensive. Using human-interpretable features extracted from H&E whole slide images with the PathExplore Breast model, together with manually assessed ER, PR, HER-2 scores, and tumor stage, PathAI, in collaboration with researchers from the Cleveland Clinic Foundation, developed interpretable models for predicting ODX recurrence scores using histological features and clinical covariates. The models achieved a level of performance comparable to previous deep-learning approaches, while also revealing the contribution of features such as cancer cell density, immune cell density, and variations in cancer nuclear shape and color to the ODX score prediction. Using readily available information, the model has the potential to be a convenient screening tool for patient stratification, which may lead to better patient care, lower costs, and faster treatment. Presenting Author: Nhat Le Time/Location: Wednesday, December 6, 12:00 PM – 2:00 PM, Poster Session 1 Poster #PO3-07-04: Prediction of PAM50 molecular subtypes from H&E-stained breast cancer specimens using tumor microenvironment features and additive multiple instance learning models PAM50, a 50-gene signature, classifies breast cancers into one of five subtypes and has emerged as a key prognostic indicator influencing treatment decisions. There is growing interest in bridging the gap between expression-based metrics and histopathology. In this poster, PathAI describes a computer vision-based approach to predict PAM50 classification using H&E-stained whole slide images (WSIs). Two separate machine learning approaches were developed to predict PAM50 subtypes from WSIs. Both models performed well in predicting Basal, Luminal A, Luminal B, and Luminal (A+B) subtypes, and provide biological interpretability not found in typical black-box models. The results support the notion that AI-powered digital pathology can accurately and reproducibly perform molecular-based classification tasks such as predicting PAM50 classifications using WSIs, suggesting a more efficient path toward clinically relevant breast cancer characterization. Presenting Author: Nhat Le Time/Location: Thursday, December 7, 12:00 PM – 2:00 PM CT, Poster Session 3 Poster #PO1-15-01: Digital pathology models reveal case-specific characteristics of the tumor microenvironment Tumor microenvironments are complex three-dimensional structures, but often only single histological sections are used to glean biological information for research purposes or in some diagnostic practices. These conclusions can also be affected by technical factors in slide preparation and digitization. In this research, PathAI applied PathExplore, a suite of digital pathology models to identify cell and tissue substances as well as their spatial relationships, to whole-slide images of breast cancer tumors and quantified intra- and inter-tumor heterogeneity in human-interpretable features of the tumor microenvironment. The results reveal biological and technical variability that can inform selection and interpretation of biomarkers derived from single slides. The ability to uniquely identify slides from the same case additionally demonstrates the technical robustness of digital pathology models for yielding quantitative insights into tumor biology. Presenting Author: Ylaine Gerardin Time/Location: Wednesday, December 6, 12:00 PM – 2:00 PM, Poster Session 1 Poster #PO2-14-12: Accurate quantification of slide-level HER2 scores in breast cancer using a machine-learning model, AIM-HER2 Breast Cancer The HER2 biomarker is critical in determining a breast cancer treatment course. To aid accurate interpretation of HER2-stained breast cancer specimens, PathAI developed the AIM-HER2 machine learning model, which demonstrates that the model performs comparably to pathologists in the prediction of HER2 scores (0-3+), including HER2-low. Comparable concordance between AIM-HER2 and pathologists was also observed irrespective of the HER2 antibody clone or slide scanner used. AIM-HER2 was developed using “Additive Multiple Instance Learning,” a novel technique which yields highly explainable results as slide-level scores and heatmaps, thereby supporting future use in AI-assisted pathologist workflows. Presenting Author: John Shamshoian Time/location: Wednesday, December 6, 5:00 – 7:00 PM CT, Poster Session 2 For more information, visit our poster sessions. For BioPharma opportunities, reach out to meet with our team at bd@pathai.com. To get in touch with our Digital Diagnostics team, reach out to digitaldx@pathai.com. For Academic Research opportunities, reach out to ryan.leung@pathai.com and liz.thomas@pathai.com *PathExplore and AIM-HER2 are For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications. PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

December 05, 2023 12:00 PM Eastern Standard Time

Image

Intelligent Health 2023 Global Summit Features Keynote by AI Luminary Tom Lawry

1BusinessWorld

The Intelligent Health 2023 Global Summit, a cornerstone event for healthcare innovation, is proud to announce a must-attend session, “The Intelligent Health Revolution is Upon Us. Are You Ready?” featuring Tom Lawry, the Managing Director of Second Century Tech. Scheduled for December 11, 2023, from 1:00 pm to 1:30 pm, this virtual event promises to be a beacon of knowledge for healthcare professionals, technologists, and innovators worldwide. https://1businessworld.com/2023-intelligent-health-summit/ Tom Lawry, a globally recognized AI keynote speaker and a transformative advisor in health and medical fields, will lead the session. Lawry's extensive career includes notable roles such as National Director for AI for Health and Life Sciences and Director of Worldwide Health at Microsoft. He is also the acclaimed author of “Hacking Healthcare – How AI and the Intelligent Health Revolution Will Reboot an Ailing System.” His thought leadership has been featured in prestigious publications like Forbes, CEO Magazine, and Harvard Business Review. The session will delve into the burgeoning Intelligent Health Revolution, with a focus on the integration and profound impact of AI in healthcare. Lawry will share his invaluable insights on how AI is reshaping healthcare delivery, enhancing patient engagement, and boosting system efficiency. He will also discuss adaptive strategies for healthcare organizations in this rapidly evolving technological landscape. Tom Lawry’s unique blend of expertise and experience positions him as a visionary voice at the intersection of technology and healthcare. Attendees will benefit from his perspectives, shaped by his roles as a health system executive and board member. This session is a rare opportunity for attendees to engage with one of the most influential voices in healthcare technology, as recognized by a Harris Poll of attendees at the 2023 JP Morgan Healthcare Conference. The Intelligent Health 2023 Global Summit, produced by the Intelligent Health Association and powered by 1BusinessWorld, is dedicated to exploring the future of healthcare. This session with Tom Lawry is a testament to the summit’s commitment to bringing the forefront of healthcare innovation to a global audience. We invite healthcare professionals, technologists, and anyone interested in the future of health and AI to join this enlightening session. Register now to secure your virtual seat and be part of the Intelligent Health Revolution. https://1businessworld.com/2023-intelligent-health-summit/ All news and content distribution in partnership with News Direct. About the Intelligent Health Association: The Intelligent Health Association (IHA) is a global consortium of healthcare and technology leaders committed to advancing digital healthcare. Our goal is to disseminate unbiased information on innovative technologies that enhance patient care and improve clinical and business processes. The IHA champions the transformation of healthcare through high-quality educational programs and networking events, facilitating the adoption and implementation of new technologies in health and wellness ecosystems. We are dedicated to reshaping healthcare through innovation and leadership, ensuring a future where technology seamlessly integrates with patient care. Intelligent Health Association About 1BusinessWorld: 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

December 05, 2023 10:54 AM Eastern Standard Time

Image

Introducing Sulinu

Sulinu

Sulinu, the trailblazing company transforming the approach to pre- and post-operative nutritional care, announces its official launch. Established by the highly regarded Clinical Dietitian, Kylie Bensley MS, RD, Sulinu introduces a paradigm shift with her comprehensive nutrition programs incorporating clinically-proven ingredients to enhance preparation for and recovery from elective procedures. As the first company of its kind, Sulinu is poised to make a profound impact on the cosmetic surgery industry, setting new standards for patient care and outcomes. Boasting over a decade of experience as a distinguished expert in nutrition, Bensley has dedicated her career to working with esteemed hospital post-surgical facilities in Cambridge and Boston, MA. Through this experience, she observed the challenges hindering proper healing and the consequent damage to the body resulting from insufficient nutrients for optimal repair. What makes Sulinu truly groundbreaking and a category innovator is that has created: The inaugural and most complete surgical recovery powder on the market and the ONLY medical-grade one available to consumers An All-IN-ONE powder that delivers vital bioavailable ingredients to the bloodstream for optimal recovery, including proteins, collagen, vitamins, enzymes, minerals and amino acids. A cleaner and more wholesome alternative to the enteral and oral nutritional supplements utilized in leading surgical facilities The ONLY powder of its kind to completely dissolve in liquid A once-daily, superblend scoop delivers immune-boosting, mind-calming and incision-healing properties for optimal nutrition and recovery Sulinu stands at the forefront of innovations in cosmetic surgery nutrition, ensuring that individuals can now navigate their surgical journeys with enhanced support and optimal well-being. By pioneering a program that underscores the importance of gut health in incision healing, Bensley simplifies and streamlines the dietary process for the body to bolster immunity, minimize swelling, alleviate bruising and fill nutrient gaps. "Nutrition is a fundamental yet often overlooked aspect of the cosmetic surgery journey,” says Bensley. “Sulinu was born out of the belief that individuals deserve inclusive, expert-guided nutrition plans to optimize their surgical experience, from preparation to recovery." The Sulinu program is designed with three key components that work collectively to combat the factors known to impair incision healing, increase infection risk, and delay overall downtime. 1. Before + After Vitals Dietary Powder Supplement*: An all-in-one gluten-free powder formulated with patented ingredients to deliver the essential and crucial nutrients needed before and after surgery. Bioenhanced Vitamin C – clinically proven to reduce inflammation and help grow and repair body tissue Proteolytic Enzymes - helps absorb protein and reduce the amount that’s excreted when combined with other proteins, increasing the absorption of total serum amino acids, which are essential for incision healing Hydrolyzed Collagen - stimulates skin cells to produce more collagen, essential to giving skin structure, strength and elasticity Biome Synbiotics – blend of both patented prebiotics and patented probiotics clinically proven to survive stomach acids and arrive alive in the gut to support a healthy microbiome. 2. Pre-Op Meal Guide. This extensive guide not only prepares the body to fast-track beautiful results, it also helps navigate dietary pitfalls that can contribute to experiencing dangerous complications. All recipes are carefully curated with ingredients that work together to turbocharge healing in efforts to avoid excessive bruising, swelling and slow-to-mend incisions. 3. Comprehensive 2-Week Post-Op Meal Plan. Tailored to specific cosmetic procedures (tummy, face, breast), each delicious, nutrient-rich, high-protein recipe is designed to alleviate nausea, pain, constipation, and optimize skin healing. Every ingredient serves a specific post-surgery recovery purpose (i.e. flax for fiber, bone broth for absorbable amino acids, turmeric for anti-inflammatory effects). Sulinu stemmed from Bensly’s frustrations in witnessing patients being prescribed multiple vitamins to augment protein powders. This not only proved costly for the patient, but ineffective because supplement dosages were incorrect and were not paired with ingredients that helped maximize absorption. This often disrupted the patient’s gut biome and hindered healing. Sulinu makes accessing the most effective and clinically proven nutrition available while also offering: Expert Guidance from a Registered Dietitian: With Kylie Bensley at the helm, Sulinu provides access to expert guidance from a registered dietitian with a wealth of knowledge in both nutrition and the specific requirements of cosmetic surgery patients. Pre-Operative Optimization: Sulinu emphasizes the importance of pre-operative nutrition to prepare the body for surgery. Through specialized dietary recommendations, clients can enhance their resilience and support their bodies in the lead-up to their cosmetic procedures. Post-Operative Recovery Support: Sulinu's post-operative nutrition plans are designed to accelerate recovery, reduce inflammation, and promote optimal healing. These plans address the unique nutritional needs that arise after cosmetic surgery, contributing to a smoother and more comfortable recovery process. Evidence-Based Approach: Sulinu is committed to an evidence-based approach, incorporating the latest research in nutrition science to guide its recommendations. This ensures that clients receive the most up-to-date and effective nutritional support throughout their cosmetic surgery journey. * Many supplements rely solely on third-party testing, which only states the presence of the vitamin. Sulinu also uses patented ingredients to ensure effectiveness at the clinically studied amounts. Recognized as safe by FDA (GRAS-affirmed): a much harder accreditation to achieve than those of standard supplement safety. Price and Availability: All-in-One Starter Kit: $297-$347 Before + After Vitals: $97 / 20 servings (1 pouch) Pre-Op Meal Guide: $97 Post-Op Meal Plan: $197-$294 Contacts: Find us: sulinu.com Follow us: LinkedIn · IG · TikTok · Facebook: # # # PR contacts: JJBPR Tara@jjbpr.com Jennifer@jjbpr.com Contact Details JJBPR Jennifer Bickerton +1 917-968-7763 jennifer@jjbpr.com JJBPR jennifer bickerton jennifer@jjbpr.com JJBPR Tara Watnik Tara@jjbpr.com Company Website https://www.sulinu.com

December 05, 2023 10:00 AM Eastern Standard Time

1 ... 68 69 70 71 72 ... 302